OCUL vs. ANIP

Last updated Apr 1, 2026

Compare and contrast key facts about Ocular Therapeutix, Inc. (OCUL) and ANI Pharmaceuticals, Inc. (ANIP).

Performance

OCUL vs. ANIP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Ocular Therapeutix, Inc. (OCUL) and ANI Pharmaceuticals, Inc. (ANIP). The values are adjusted to include any dividend payments, if applicable.

OCUL vs. ANIP - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
OCUL Ocular Therapeutix, Inc.	-30.23%	42.15%	91.48%	58.72%	-59.68%	-66.33%	424.05%	-0.75%	-10.56%	-46.83%
ANIP ANI Pharmaceuticals, Inc.	-2.58%	42.80%	0.25%	37.06%	-12.70%	58.68%	-52.91%	36.98%	-30.15%	6.32%

Fundamentals

Market Cap OCUL : $1.89B ANIP : $1.63B
EPS OCUL : -$1.38 ANIP : $3.75
PS Ratio OCUL : 31.49 ANIP : 1.82
PB Ratio OCUL : 2.89 ANIP : 3.02
Total Revenue (TTM) OCUL : $51.95M ANIP : $883.37M
Gross Profit (TTM) OCUL : $45.25M ANIP : $610.19M
EBITDA (TTM) OCUL : -$258.96M ANIP : $225.70M

Returns By Period

In the year-to-date period, OCUL achieves a -30.23% return, which is significantly lower than ANIP's -2.58% return. Over the past 10 years, OCUL has underperformed ANIP with an annualized return of -1.51%, while ANIP has yielded a comparatively higher 8.52% annualized return.

OCUL

• 1D: 14.46%
• 1M: -5.26%
• YTD: -30.23%
• 6M: -27.54%
• 1Y: 15.55%
• 3Y*: 17.14%
• 5Y*: -13.42%
• 10Y*: -1.51%

ANIP

• 1D: 4.33%
• 1M: 4.06%
• YTD: -2.58%
• 6M: -16.05%
• 1Y: 14.86%
• 3Y*: 24.63%
• 5Y*: 17.71%
• 10Y*: 8.52%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

OCUL vs. ANIP — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

OCUL

OCUL Risk / Return Rank: 50
OCUL Sharpe Ratio Rank: 50
OCUL Sortino Ratio Rank: 53
OCUL Omega Ratio Rank: 52
OCUL Calmar Ratio Rank: 47
OCUL Martin Ratio Rank: 48

ANIP

ANIP Risk / Return Rank: 54
ANIP Sharpe Ratio Rank: 57
ANIP Sortino Ratio Rank: 54
ANIP Omega Ratio Rank: 52
ANIP Calmar Ratio Rank: 53
ANIP Martin Ratio Rank: 52

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

OCUL vs. ANIP - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Ocular Therapeutix, Inc. (OCUL) and ANI Pharmaceuticals, Inc. (ANIP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	OCUL	ANIP	Difference
Sharpe ratio Return per unit of total volatility	0.21	0.40	-0.20
Sortino ratio Return per unit of downside risk	0.91	0.93	-0.02
Omega ratio Gain probability vs. loss probability	1.11	1.11	0.00
Calmar ratio Return relative to maximum drawdown	0.20	0.48	-0.27
Martin ratio Return relative to average drawdown	0.52	0.97	-0.45
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

OCUL vs. ANIP - Sharpe Ratio Comparison

The current OCUL Sharpe Ratio is 0.21, which is lower than the ANIP Sharpe Ratio of 0.40. The chart below compares the historical Sharpe Ratios of OCUL and ANIP, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	OCUL	ANIP	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.21	0.40	-0.20
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.17	0.38	-0.55
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.02	0.18	-0.19
Sharpe Ratio (All Time) Calculated using the full available price history	-0.05	-0.05	+0.01

Correlation

The correlation between OCUL and ANIP is 0.31, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

OCUL vs. ANIP - Dividend Comparison

Neither OCUL nor ANIP has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

OCUL vs. ANIP - Drawdown Comparison

The maximum OCUL drawdown since its inception was -95.19%, roughly equal to the maximum ANIP drawdown of -98.81%. Use the drawdown chart below to compare losses from any high point for OCUL and ANIP.

Drawdown Indicators

	OCUL	ANIP	Difference
Max Drawdown Largest peak-to-trough decline	-95.19%	-98.81%	+3.62%
Max Drawdown (1Y) Largest decline over 1 year	-57.29%	-28.66%	-28.63%
Max Drawdown (5Y) Largest decline over 5 years	-89.14%	-59.38%	-29.76%
Max Drawdown (10Y) Largest decline over 10 years	-90.94%	-72.96%	-17.98%
Current Drawdown Current decline from peak	-80.43%	-82.91%	+2.48%
Average Drawdown Average peak-to-trough decline	-76.58%	-79.38%	+2.80%
Ulcer Index Depth and duration of drawdowns from previous peaks	22.71%	14.22%	+8.49%

Volatility

OCUL vs. ANIP - Volatility Comparison

Ocular Therapeutix, Inc. (OCUL) has a higher volatility of 19.52% compared to ANI Pharmaceuticals, Inc. (ANIP) at 9.44%. This indicates that OCUL's price experiences larger fluctuations and is considered to be riskier than ANIP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	OCUL	ANIP	Difference
Volatility (1M) Calculated over the trailing 1-month period	19.52%	9.44%	+10.08%
Volatility (6M) Calculated over the trailing 6-month period	58.02%	22.59%	+35.43%
Volatility (1Y) Calculated over the trailing 1-year period	75.47%	36.90%	+38.57%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	78.73%	47.10%	+31.63%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	80.20%	48.62%	+31.58%

Financials